

Medical drug benefit *Clinical Criteria* updates

On November 19, 2021, January 4, 2022, and February 25, 2022, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the **medical drug benefit** for Empire BlueCross BlueShield HealthPlus. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. If you have questions or would like additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical policy. This does not apply to pharmacy services.

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
June 9, 2022	*ING-CC-0211	Kimmtrak (tebentafusp-tebn)	New
June 9, 2022	*ING-CC-0210	Enjaymo (sutimlimab-jome)	New
June 9, 2022	*ING-CC-0213	Voxzogo (vosoritide)	New
June 9, 2022	*ING-CC-0212	Tezspire (tezepelumab-ekko)	New
June 9, 2022	*ING-CC-0086	Spravato (esketamine) Nasal Spray	Revised
June 9, 2022	ING-CC-0157	Padcev (enfortumab vedotin)	Revised
June 9, 2022	ING-CC-0125	Opdivo (nivolumab)	Revised
June 9, 2022	ING-CC-0119	Yervoy (ipilimumab)	Revised
June 9, 2022	*ING-CC-0099	Abraxane (paclitaxel, protein bound)	Revised
June 9, 2022	ING-CC-0120	Kyprolis (carfilzomib)	Revised
June 9, 2022	ING-CC-0126	Blinicyto (blinatumomab)	Revised
June 9, 2022	ING-CC-0129	Bavencio (avelumab)	Revised
June 9, 2022	*ING-CC-0090	Ixempra (ixabepilone)	Revised
June 9, 2022	ING-CC-0110	Perjeta (pertuzumab)	Revised
June 9, 2022	ING-CC-0115	Kadcyla (ado-trastuzumab)	Revised
June 9, 2022	ING-CC-0108	Halaven (eribulin)	Revised
June 9, 2022	*ING-CC-0033	Xolair (omalizumab)	Revised
June 9, 2022	*ING-CC-0043	Monoclonal Antibodies to Interleukin-5	Revised
June 9, 2022	ING-CC-0038	Human Parathyroid Hormone Agents	Revised

<https://providerpublic.empireblue.com>

Empire BlueCross BlueShield HealthPlus is the trade name of HealthPlus HP, LLC, an independent licensee of the Blue Cross and Blue Shield Association.

NYE-NU-0432-22 April 2022

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
June 9, 2022	*ING-CC-0186	Marginza (margetuximab-cmkb)	Revised
June 9, 2022	*ING-CC-0124	Keytruda (pembrolizumab)	Revised
June 9, 2022	*ING-CC-0078	Orencia (abatacept)	Revised
June 9, 2022	ING-CC-0050	Monoclonal Antibodies to Interleukin-23	Revised
June 9, 2022	ING-CC-0042	Monoclonal Antibodies to Interleukin-17	Revised
June 9, 2022	*ING-CC-0029	Dupixent (dupilumab)	Revised
June 9, 2022	*ING-CC-0208	Adbry (tralokinumab)	Revised
June 9, 2022	*ING-CC-0209	Leqvio (inclisiran)	Revised
June 9, 2022	*ING-CC-0166	Trastuzumab Agents	Revised
June 9, 2022	*ING-CC-0107	Bevacizumab for Non-ophthalmologic Indications	Revised



Email is the quickest and most direct way to receive important information from Empire BlueCross BlueShield HealthPlus.

To start receiving email from us (including some sent in lieu of fax or mail), submit your information using the QR code to the right or via our online form (<https://bit.ly/3zqQdYB>).

